Ata Türker ARIKÖK, Evrim ÖNDER, Binnur ÖNAL, Engin Deniz YILMAZ

Prostatik Adenokarsinomlarda Claudin-3’ ün Tanısal Değeri: AMACR ile Karşılaştırmalı İmmunohistokimyasal Çalışma

Amaç: Claudin protein ailesinin çeşitli kanserlerde aşırı ekspresyonu gösterilmiştir. Prostatik dokularda Claudin-3 ekspresyonunu araştırmayı ve prostatik karsinomlarda tanısal önemini değerlendirmeyi hedefledik. Gereç ve Yöntem: Sağlık Bakanlığı Ankara Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi arşivine ait 50 prostatik adenokarsinom olgusu değerlendirilmiştir. Herbir vakaya ait bir parafin blok seçilmiştir. Alpha-methylacyl-CoA racemase (AMACR) ve Claudin-3 immunohistokimyasal belirteçler için her bloktan iki kesit hazırlanmıştır. Adenokarsinom, benign gland ve yüksek dereceli prostatik intraepitelyal neoplazi alanları her kesitte ayrı ayrı değerlendirilmiş olup, boyanma yoğunlukları 0-2 arasında skorlanmıştır. Bulgular: İmmunohistokimyasal değelendirme sonrası, Prostatik karsinomların %94.1'i Claudin-3 ile pozitiflik gösterirken, bu oran AMACR ile %77.4’dür. Ayrıca Prostatik intraepitelyal neoplazi alanlarında, Claudin-3 ile pozitif boyanma oranları, AMACR’a göre daha yüksektir (p

The Utility of Claudin-3 in Diagnosis of Prostatic Adenocarcinoma: A Comparative Immunohistochemical Study with AMACR

Objective: Claudin family of proteins has been shown to be overexpressed in various cancers. We aimed to investigate one member of this family, the Claudin-3 expressions in prostate tissue and evaluate its utility as a diagnostic marker for prostatic adenocarcinoma. Material and Method: A total number of 50 cases of prostatic adenocarcinoma were reviewed from the files of M.H Ankara Dışkapı Research and Training Hospital. One paraffin block was selected for each case. For separate immunohistochemical staining with Alpha-methylacyl-CoA racemase (AMACR) and Claudin-3, two slides were sectioned from each block. Prostatic carcinoma (PC), Benign gland, and High grade prostatic intraepithealial neoplasia (HGPIN) components in each slide were evaluated. Afterwards the intensity of stainings were scored on a scale of 0-2 seperately for each component. Results: After immunohistochemical evaluation, 94.1% of PC showed positivity with Claudin-3 whereas this value was 77.4% for AMACR. Furt- hermore in the areas of HGPIN, the positivity rates with Claudin-3 was also higher than those of AMACR (p

PDF

___

1. Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol 2007; 60: 35-42.
2. Hameed O, Sublett J, Humphrey PA. Immunohis- tochemical stains for p63 and alpha- methylacyl3. Puebla-Mora AG, Heras A, Cano-Valdez AM, Dominguez-Malagon H. Human telomerase and α-methylacyl-coenzyme A racemase in prostatic carcinoma. A comperative immunohistochemical study. Ann Diagn Pathol 2006; 10: 205-8.
4. Herawi M, Epstein JI. Immunohistochemical anti- body coctail staining (p63, HMWCK, AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and non-cribriform aciner adenocarci- nomas of prostate. Am J Surg Pathol 2007; 31: 889-94.
5. Tsukita S, Furuse M. Pores in the wall: clau- dins constitute tight junction strands containing aqueous pores. J Cell Biol 2000; 149: 13-6.
6. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Natl Rev Mol Cell Biol 2001; 2: 285-93.
7. Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005; 65: 9603-6.
8. Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 2006; 6: 186.
9. Choi YL, Kim J, Kwon MJ et al. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarsinoma with prognostic correlation. Histol Histopathol 2007; 22: 1185-95.
10. Soini Y, Kinnula V, Kahlos K, Paakko P. Clau- dins in differential diagnosis between mesotheli- oma and metastatic adenocarcinoma of the pleura. J Clin Pathol 2006; 59: 250-4.
11. Lechpammer M, Resnick MB, Sabo Eİ Yakirevic E et al. The diagnostic and prognostic utility of claudin expression in renal cell neoplasms. Mod Pathol 2008; 21: 1320-9.
12. Okugawa T, Oshima T, Chen Z et al. Down regu- lation of claudin-3 is associated with proliferati- ve potential in early gastric cancer. Dig Dis Sci 2012; 57: 1562-7.
13. Takala H, Saarnio J, Wiik H, Soini Y. Claudins 1, 3, 4, 5 and 7 esophagial cancer: loss of claudin-3 and 4 expression is associated with metastatic be- haviour APMIS 2007; 115: 838-47.
14. Bartholow TL, Chandran UR, Becich MJ, Parwa- ni AV. Imunohistochemical profiles of claudin-3 in primary and metastatic prostatic adenocarcino- ma. Diagn Pathol 2011; 21: 6-12.
15. Countinho-Camillo CM, Lourenco SV, da Fonseca FP, Soares FA. Claudin expression is dysregula- ted in prostate adenocarcinomas but does not correlate with main clinicopathological parame- ters. Pathology 2011; 43: 143-8.
16. Väre P, Loikkanen I, Hırvıkoskı P, Vaarala M.H, Soini Y. Low claudin expression is associated with high Gleason grade in prostate adenocarcino- ma. Oncol Rep 2008; 19: 25-31
17. Elbe JN, Sauter G, Epstein JI, Sesterhenn IA. (Eds) (2010) World Health Organization of Classification of Tumours. Pathology and Gene- tics of Tumours of the Urinary System and Male Genital Organs. IARC Press, Lyon.
18. Evans A J. α-Methylacyl CoA racemase (P504S): overview and potential uses in diag- nostic pathology as applied to prostate needle biop- sies. J Clin Pathol 2003; 56: 892-7.
19. Oh JW, Kim YB, Yang SO et al. Prostate cancer detection rate of rebiopsy in patients with an ini- tial diagnosis of atypical small acinar proliferation of the prostate. Korean J Urol 50: 237-40.
20. Jiang Z, Iczkowski KA, Woda BA, Tretiakova M, Yang XJ. P504S, immunostaining boosts diag- nostic resolution of “suspicious” foci in prostatic needle biopsy specimens. Am J Clin Pathol 2004; 121: 99-107.
21. Kumaresan K, Kakkar N, Verma A, Mandal AK, Singh SK, Joshi K. Diagnostic utility of α- methylacyl CaA racemase (P504S) and HMWCK in morphologically difficult prostate cancer. Di- agn Pathol 2010; 5: 83.
22. Ertoy Baydar D. Prostat kanser patolojisi. Trd Sem 2017; 5: 370-82.